Evidence map›Paper›PMID 26378277›Full record

ArticleJournal of clinical microbiology2015

Metabolomic Profiling of Plasma from Patients with Tuberculosis by Use of Untargeted Mass Spectrometry Reveals Novel Biomarkers for Diagnosis.

Susanna K P Lau, Kim-Chung Lee, Shirly O T Curreem, Wang-Ngai Chow, Kelvin K W To, Ivan F N Hung, Deborah T Y Ho, Siddharth Sridhar, Iris W S Li, Vanessa S Y Ding and 6 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of clinical microbiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 55 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Trends and challenges of multi-drug resistance in childhood tuberculosis.Frontiers in cellular and infection microbiology · 2023
    Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Using Omics to Study Leprosy, Tuberculosis, and Other Mycobacterial Diseases.Frontiers in cellular and infection microbiology · 2022
    Review
  19. Host lipidome and tuberculosis treatment failure.The European respiratory journal · 2022
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 2 countries.

Susanna K P LauState Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong, Hong Kong Research Centre of Infection and Immunology, The University of Hong Kong, Hong Kong Carol Yu Centre for Infection, The University of Hong Kong, Hong Kong Department of Microbiology, The University of Hong Kong, Hong Kong skplau@hku.hk pcywoo@hku.hk.
Kim-Chung LeeDepartment of Microbiology, The University of Hong Kong, Hong Kong.
Shirly O T CurreemDepartment of Microbiology, The University of Hong Kong, Hong Kong.
Wang-Ngai ChowDepartment of Microbiology, The University of Hong Kong, Hong Kong.ORCID http://orcid.org/0000-0003-1275-2464
Kelvin K W ToState Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong, Hong Kong Research Centre of Infection and Immunology, The University of Hong Kong, Hong Kong Carol Yu Centre for Infection, The University of Hong Kong, Hong Kong Department of Microbiology, The University of Hong Kong, Hong Kong.
Ivan F N HungResearch Centre of Infection and Immunology, The University of Hong Kong, Hong Kong Department of Medicine, The University of Hong Kong, Hong Kong.
Deborah T Y HoDepartment of Microbiology, The University of Hong Kong, Hong Kong.
Siddharth SridharDepartment of Microbiology, The University of Hong Kong, Hong Kong.
Iris W S LiDepartment of Microbiology, The University of Hong Kong, Hong Kong.
Vanessa S Y DingDepartment of Microbiology, The University of Hong Kong, Hong Kong.
Eleanor W F KooDepartment of Pathology, Grantham Hospital, Hong Kong.
Chi-Fong WongTuberculosis & Chest Unit, Grantham Hospital, Hong Kong.
Sidney TamDepartment of Pathology, The University of Hong Kong, Hong Kong.
Ching-Wan LamDepartment of Pathology, The University of Hong Kong, Hong Kong.
Kwok-Yung YuenState Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong, Hong Kong Research Centre of Infection and Immunology, The University of Hong Kong, Hong Kong Carol Yu Centre for Infection, The University of Hong Kong, Hong Kong Department of Microbiology, The University of Hong Kong, Hong Kong.
Patrick C Y WooState Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong, Hong Kong Research Centre of Infection and Immunology, The University of Hong Kong, Hong Kong Carol Yu Centre for Infection, The University of Hong Kong, Hong Kong Department of Microbiology, The University of Hong Kong, Hong Kong skplau@hku.hk pcywoo@hku.hk.
University of Hong Kong · HKGrantham Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although tuberculosis (TB) is a reemerging disease that affects people in developing countries and immunocompromised populations in developed countries, the current diagnostic methods are far from optimal. Metabolomics is increasingly being used for studies on infectious diseases. We performed metabolome profiling of plasma samples to identify potential biomarkers for diagnosing TB. We compared the plasma metabolome profiles of TB patients (n = 46) with those of community-acquired pneumonia (CAP) patients (n = 30) and controls without active infection (n = 30) using ultrahigh-performance liquid chromatography-electrospray ionization-quadrupole time of flight mass spectrometry (UHPLC-ESI-QTOFMS). Using multivariate and univariate analyses, four metabolites, 12R-hydroxy-5Z,8Z,10E,14Z-eicosatetraenoic acid [12(R)-HETE], ceramide (d18:1/16:0), cholesterol sulfate, and 4α-formyl-4β-methyl-5α-cholesta-8-en-3β-ol, were identified and found to have significantly higher levels in TB patients than those in CAP patients and controls. In a comparison of TB patients and controls, the four metabolites demonstrated area under the receiver operating characteristic curve (AUC) values of 0.914, 0.912, 0.905, and 0.856, sensitivities of 84.8%, 84.8%, 87.0%, and 89.1%, specificities of 90.0%, 86.7%, 86.7%, and 80.0%, and fold changes of 4.19, 26.15, 6.09, and 1.83, respectively. In a comparison of TB and CAP patients, the four metabolites demonstrated AUC values of 0.793, 0.717, 0.802, and 0.894, sensitivities of 89.1%, 71.7%, 80.4%, and 84.8%, specificities of 63.3%, 66.7%, 70.0%, and 83.3%, and fold changes of 4.69, 3.82, 3.75, and 2.16, respectively. 4α-Formyl-4β-methyl-5α-cholesta-8-en-3β-ol combined with 12(R)-HETE or cholesterol sulfate offered ≥70% sensitivity and ≥90% specificity for differentiating TB patients from controls or CAP patients. These novel plasma biomarkers, especially 12(R)-HETE and 4α-formyl-4β-methyl-5α-cholesta-8-en-3β-ol, alone or in combination, are potentially useful for rapid and noninvasive diagnosis of TB. The present findings may offer insights into the pathogenesis and host response in TB.

Indexed as

MetabolomeAdolescentAdultAgedAged, 80 and overBiomarkersChromatography, LiquidFemaleHumansMaleMass SpectrometryMiddle AgedPlasmaROC CurveSensitivity and SpecificityTuberculosisBiomarkers

Identifiers

PMID26378277
PMCPMC4652110
OpenAlexW1466493721

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.